MorphoSys (MOR) PT Set at €114.00 by Goldman Sachs Group
MorphoSys (ETR:MOR) has been given a €114.00 ($132.56) price objective by equities researchers at Goldman Sachs Group in a report issued on Monday. The firm presently has a “neutral” rating on the stock. Goldman Sachs Group’s price objective suggests a potential upside of 36.36% from the stock’s current price.
MOR has been the topic of a number of other reports. Independent Research set a €104.00 ($120.93) price target on shares of MorphoSys and gave the company a “neutral” rating in a research note on Wednesday, November 28th. Berenberg Bank set a €108.00 ($125.58) target price on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Thursday, February 28th. Deutsche Bank set a €125.00 ($145.35) target price on shares of MorphoSys and gave the stock a “buy” rating in a research note on Tuesday, January 29th. Royal Bank of Canada set a €65.00 ($75.58) target price on shares of MorphoSys and gave the stock a “sell” rating in a research note on Monday, December 3rd. Finally, JPMorgan Chase & Co. set a €135.00 ($156.98) target price on shares of MorphoSys and gave the stock a “buy” rating in a research note on Monday, January 14th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of €101.30 ($117.79).
MorphoSys stock opened at €83.60 ($97.21) on Monday. The company has a market capitalization of $2.64 billion and a PE ratio of -93.41. MorphoSys has a 1 year low of €76.45 ($88.90) and a 1 year high of €124.90 ($145.23). The company has a current ratio of 11.51, a quick ratio of 11.21 and a debt-to-equity ratio of 0.01.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Recommended Story: Cost of Equity For A Business, Investors
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.